MSD’s trial of drug for pulmonary arterial hypertension meets primary endpoint
US-based pharmaceutical company MSD has reported that the Phase III ZENITH trial of WINREVAIR (sotatercept-csrk) for pulmonary arterial hypertension (PAH)…
US-based pharmaceutical company MSD has reported that the Phase III ZENITH trial of WINREVAIR (sotatercept-csrk) for pulmonary arterial hypertension (PAH)…
Shanghai Ark Biopharmaceutical (ArkBio) has concluded enrolment and dosing for a Phase I trial of fully human monoclonal antibody, AK0610,…
Endeavor BioMedicines has dosed the first subject in the randomised Phase IIb WHISTLE-PF trial in Australia, assessing the efficacy and…
MSD has reported positive topline outcomes from the Phase III MK-3475A-D77 study assessing the noninferiority of subcutaneous Keytruda (pembrolizumab) administration,…
Boston-based Paratek Pharmaceuticals has released positive topline data from a Phase IIb trial evaluating its oral antibiotic Nuzyra (omadacycline) in…
Qnovia has received clearance from the US Food and Drug Administration (FDA) to start a clinical trial for its RespiRX…
GSK’s asthma drug Nucala (mepolizumab) has met the primary endpoint in a Phase III trial treating patients with chronic obstructive…
This week on Pipeline Moves, we kick off by looking at a Phase II termination of an investigator-led trial of…
The University of Dundee in the UK is set to lead a clinical trial investigating whether existing medications can effectively…
The chronic obstructive pulmonary disorder (COPD) market has laid relatively dormant for the past few years until recently. Several biologics…